Abbott Laboratories (ABT) reported quarterly earnings results on Wednesday, Jul-20-2016. The company said it had a profit of $0.55 Earnings per Share for the quarter. The results exceeded Wall Street expectations beating the analyst consensus estimate by $0.02. Analysts had a consensus of $0.53. The company posted revenue of $5333.00 million in the period, compared to analysts expectations of $5244.94 million. The company’s revenue was up 3.2% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.52 EPS.
Many Wall Street Analysts have commented on Abbott Laboratories. Abbott Laboratories was Upgraded by Edward Jones to ” Buy” on Jun 21, 2016.
Abbott Laboratories closed down -0.01 points or -0.02% at $42.09 with 75,24,201 shares getting traded on Monday. Post opening the session at $42.05, the shares hit an intraday low of $41.81 and an intraday high of $42.229 and the price fluctuated in this range throughout the day.Shares ended Monday session in Red.
In a different news, on Jun 30, 2016, Hubert L Allen (Executive Vice President) sold 3,400 shares at $37.14 per share price. According to the SEC, on Jun 17, 2016, Jared Watkin (Senior Vice President) sold 552 shares at $37.63 per share price. On Jun 3, 2016, Brian B Yoor (Senior Vice President and CFO) sold 565 shares at $39.49 per share price, according to the Form-4 filing with the securities and exchange commission.
Abbott Laboratories (Abbott) is engaged in the discovery development manufacture and sale of a range of health care products. Abbott operates in four business segments: Established Pharmaceutical Products Diagnostic Products Nutritional Products and Vascular Products. The Established Pharmaceutical Products segment includes the international sales of a line of branded generic pharmaceutical products. The Diagnostic Products segment includes the sales of a line of adult and pediatric nutritional products. The Nutritional Products includes the sales of diagnostic systems and tests for blood banks hospitals commercial laboratories and alternate-care testing sites. The Vascular Products includes the sales of coronary endovascular structural heart vessel closure and other medical device products.